76 filings
8-K
EOLS
Evolus Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:59pm
8-K
EOLS
Evolus Inc
7 Mar 24
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
4:09pm
8-K
EOLS
Evolus Inc
16 Jan 24
Evolus Announces Preliminary Unaudited Fourth Quarter
5:28pm
8-K
EOLS
Evolus Inc
20 Dec 23
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
8:33am
8-K
EOLS
Evolus Inc
7 Nov 23
Evolus Reports Record Third Quarter 2023 Financial Results
4:24pm
8-K
6ltemmy5
2 Aug 23
Evolus Reports Second Quarter 2023 Results
4:08pm
8-K
vfgph3
27 Jul 23
Results of Operations and Financial Condition
8:55am
8-K
9rx9vt l75pa4c35
14 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:39pm
8-K
domsu02 1gq3
9 May 23
Evolus Reports First Quarter 2023 Results
4:07pm
8-K
1k4u0i8
13 Mar 23
Regulation FD Disclosure
9:00am
8-K
6gm16jjrc
8 Mar 23
Evolus Reports Fourth Quarter and Full Year 2022 Results
4:09pm
8-K
mojy29syr4wfmadsj
18 Jan 23
Results of Operations and Financial Condition
8:53am
8-K
t7bjtb48 zqb8
13 Dec 22
Entry into a Material Definitive Agreement
8:38am
8-K
9brhnm66000r6c6
8 Dec 22
Entry into a Material Definitive Agreement
9:21am
8-K
7glc5v5uti7dn92blce3
8 Nov 22
Evolus Reports Third Quarter 2022 Results
4:10pm
8-K
91lbixd
30 Aug 22
Evolus Appoints Sandra Beaver as Chief Financial Officer
4:52pm
8-K
uuj9ka
2 Aug 22
Evolus Reports Second Quarter 2022 Results
8:29am
8-K
t5l114ucpjfpbckxk
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:56pm
8-K
zgb0s 7i3f
10 May 22
Evolus Reports First Quarter 2022 Results
4:07pm
8-K
abrm2sx8mgh8e67eqts
4 Mar 22
Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail
4:34pm